Page last updated: 2024-10-19

niacin and Infection

niacin has been researched along with Infection in 19 studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

ExcerptRelevanceReference
"Pellagra is a curable dietary illness that unchecked leads to dementia, diarrhoea, dermatitis and death due to lack of the precursors for NAD(H)."3.74Pellagra: A clue as to why energy failure causes diseases? ( Ramsden, DB; Williams, AC, 2007)
" However, the trial also identified previously unrecognized serious adverse effects (including new-onset diabetes, bleeding, and infection)."2.90Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. ( Armitage, J; Chen, F; Haynes, R; Hopewell, JC; Landray, MJ; Li, J; Parish, S; Valdes-Marquez, E, 2019)
"Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3."2.79Effects of extended-release niacin with laropiprant in high-risk patients. ( Armitage, J; Aung, T; Collins, R; Craig, M; Haynes, R; Hopewell, JC; Jiang, L; Landray, MJ; Parish, S; Tomson, J; Wallendszus, K, 2014)
"Local infections are often unusually severe."1.29Pellagra--increased viscosity of extracellular matrix. ( Stone, OJ, 1993)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19904 (21.05)18.7374
1990's1 (5.26)18.2507
2000's1 (5.26)29.6817
2010's13 (68.42)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Haynes, R3
Valdes-Marquez, E1
Hopewell, JC2
Chen, F1
Li, J1
Parish, S2
Landray, MJ3
Armitage, J3
Lloyd-Jones, DM1
Aung, T1
Tomson, J1
Wallendszus, K1
Craig, M1
Jiang, L1
Collins, R1
McCarthy, M1
Huynh, K1
Rembold, CM1
Meneses, F1
Hu, M1
Tomlinson, B1
van den Oever, IA1
Nurmohamed, MT1
Lems, WF1
Santos-Gallego, CG1
Badimon, J1
Mayer, L1
Bloomfield, HE1
CAYER, D1
CODY, S1
LEVENSON, SM1
GREEN, RW1
NORMAND, J1
Williams, AC1
Ramsden, DB1
Stone, OJ1
Gopalan, C1
Srikantia, SG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant[NCT00461630]Phase 325,673 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Coronary or Non-coronary Revascularisation

(NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Interventionparticipants (Number)
ER Niacin/Laropiprant807
Placebo897

Major Coronary Events

Non-fatal myocardial infarction (MI) or coronary death (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Interventionparticipants (Number)
ER Niacin/Laropiprant668
Placebo694

Major Vascular Event

Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Interventionparticipants (Number)
ER Niacin/Laropiprant1696
Placebo1758

Mortality

All-cause mortality (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Interventionparticipants (Number)
ER Niacin/Laropiprant798
Placebo732

Stroke

Fatal or non-fatal (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Interventionparticipants (Number)
ER Niacin/Laropiprant498
Placebo499

Reviews

1 review available for niacin and Infection

ArticleYear
Nutrition and disease.
    World review of nutrition and dietetics, 1973, Volume: 16

    Topics: Adult; Anemia, Hypochromic; Anemia, Macrocytic; Antibody Formation; Blood Bactericidal Activity; Chi

1973

Trials

2 trials available for niacin and Infection

ArticleYear
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
    Clinical therapeutics, 2019, Volume: 41, Issue:9

    Topics: Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; Double-Blind Method; Drug T

2019
Effects of extended-release niacin with laropiprant in high-risk patients.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Aged; Atherosclerosis; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus; Double-Blin

2014

Other Studies

16 other studies available for niacin and Infection

ArticleYear
Niacin and HDL cholesterol--time to face facts.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma

2014
Niacin fails to reduce vascular events in large randomised trial.
    BMJ (Clinical research ed.), 2014, Jul-22, Volume: 349

    Topics: Blood Glucose; Cholesterol, HDL; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combi

2014
Dyslipidaemia: Niacin-laropiprant fails to reduce the risk of vascular events.
    Nature reviews. Cardiology, 2014, Volume: 11, Issue:10

    Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma

2014
Niacin for reduction of cardiovascular risk.
    The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20

    Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma

2014
Niacin for reduction of cardiovascular risk.
    The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20

    Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma

2014
Niacin for reduction of cardiovascular risk.
    The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20

    Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma

2014
Niacin for reduction of cardiovascular risk.
    The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20

    Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma

2014
Niacin for reduction of cardiovascular risk.
    The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20

    Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma

2014
Niacin for reduction of cardiovascular risk.
    The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20

    Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma

2014
Niacin for reduction of cardiovascular risk.
    The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20

    Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma

2014
ACP Journal Club: adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events.
    Annals of internal medicine, 2014, Nov-18, Volume: 161, Issue:10

    Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma

2014
Urinary excretion of niacin and riboflavin in patients with acute infections and various chronic diseases.
    The American journal of the medical sciences, 1948, Volume: 215, Issue:3

    Topics: Acute Disease; Chronic Disease; Humans; Infections; Niacin; Nicotinic Acids; Riboflavin; Urine

1948
Ascorbic acid, riboflavin, thiamin, and nicotinic acid in relation to severe injury, hemorrhage, and infection in the human.
    Annals of surgery, 1946, Volume: 124

    Topics: Ascorbic Acid; Deficiency Diseases; Hemorrhage; Humans; Infections; Metabolism; Niacin; Nicotinic Ac

1946
[MEDICO-SURGICAL TREATMENT OF OBLITERATING ARTERIOPATHIES OF THE LOWER EXTREMITIES WITHOUT ACUTE ISCHEMIA. THE POINT OF VIEW OF THE PHYSICIAN].
    Journal de medecine de Lyon, 1964, Jan-05, Volume: 45

    Topics: Anticoagulants; Arteriosclerosis Obliterans; Autonomic Nerve Block; Embolism; Hypertonic Solutions;

1964
Pellagra: A clue as to why energy failure causes diseases?
    Medical hypotheses, 2007, Volume: 69, Issue:3

    Topics: Animals; Biochemistry; Diet; Humans; Infections; Inflammation; Metabolism; Models, Biological; Model

2007
Pellagra--increased viscosity of extracellular matrix.
    Medical hypotheses, 1993, Volume: 40, Issue:6

    Topics: Central Nervous System; Digestive System; Extracellular Matrix; Female; Glycosaminoglycans; Humans;

1993